ID | 52408 |
JaLCDOI | |
フルテキストURL | |
著者 |
Takeda, Akiko
Department of Pediatrics, Okayama University Hospital
Hamamoto, Kazuko
Department of Pediatrics, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
Yoshino, Syuuji
Department of Pediatrics, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
Nagai, Tomoko
Department of Pharmacology, Meijo University
Fujii, Yousuke
Department of Pediatrics, Okayama University Hospital
Yamada, Mutsuko
Department of Pediatrics, Okayama University Hospital
Nakamura, Yoshimi
Department of Division of Medical Support,, Okayama University Hospital
Watanabe, Toshiyuki
Department of Division of Medical Support,, Okayama University Hospital
Watanabe, Yuki
Department of Pediatrics, Okayama University Hospital
Yamamoto, Yuko
Department of Pediatrics, Okayama University Hospital
Sakakibara, Kanae
Department of Laboratory Medicine, National Hospital Organization Okayama Medical Center
Oda, Megumi
Department of Pediatric Hematology/Oncology, Okayama University Hospital
Kaken ID
publons
researchmap
Morishima, Tsuneo
Department of Pediatrics, Okayama University Hospital
|
抄録 | Acute megakaryocytic leukemia (AMKL) with t(1;22)(p13;q13) is a distinct category of myeloid leukemia by WHO classification and mainly reported in infants and young children. Accurate diagnosis of this type of AMKL can be difficult, because a subset of patients have a bone marrow (BM) blast percentage of less than 20% due to BM fibrosis. Therefore, it is possible that past studies have underestimated this type of AMKL. We present here the case of a 4-month-old female AMKL patient who was diagnosed by presence of the RBM15-MKL1 (OTT-MAL) fusion transcript by RT-PCR. In addition, we monitored RBM15-MKL1 fusion at several time points as a marker of minimal residual disease (MRD), and found that it was continuously negative after the first induction chemotherapy even by nested RT-PCR. Detection of the RBM15-MKL1 fusion transcript thus seems to be useful for accurate diagnosis of AMKL with t(1;22)(p13;q13). We recommend that the RBM15-MKL1 fusion transcript be analyzed for all suspected AMKL in infants and young children. Furthermore, monitoring of MRD using this fusion transcript would be useful in treatment of AMKL with t(1;22)(p13;q13).
|
キーワード | AMKL
infant
RBM15-MKL1
OTT-MAL
|
Amo Type | Case Report
|
出版物タイトル |
Acta Medica Okayama
|
発行日 | 2014-04
|
巻 | 68巻
|
号 | 2号
|
出版者 | Okayama University Medical School
|
開始ページ | 119
|
終了ページ | 123
|
ISSN | 0386-300X
|
NCID | AA00508441
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
著作権者 | CopyrightⒸ 2014 by Okayama University Medical School
|
論文のバージョン | publisher
|
査読 |
有り
|
PubMed ID | |
Web of Science KeyUT |